Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
February 2025's Stock Selections Possibly Priced Below Estimated Worth

In This Article:

In February 2025, global markets are experiencing a mix of optimism and caution, with U.S. stock indexes nearing record highs amid an environment of accelerating inflation and uncertain trade policies. As investors navigate these complex conditions, identifying undervalued stocks becomes crucial; such stocks may offer potential opportunities when their intrinsic value is not fully reflected in their current market price.

Top 10 Undervalued Stocks Based On Cash Flows

Name

Current Price

Fair Value (Est)

Discount (Est)

Ningbo Sanxing Medical ElectricLtd (SHSE:601567)

CN¥26.41

CN¥51.88

49.1%

Vimi Fasteners (BIT:VIM)

€0.97

€1.91

49.2%

Hibino (TSE:2469)

¥2770.00

¥5502.58

49.7%

Shanghai Haohai Biological Technology (SEHK:6826)

HK$26.30

HK$52.47

49.9%

Power Wind Health Industry (TWSE:8462)

NT$110.50

NT$220.43

49.9%

América Móvil. de (BMV:AMX B)

MX$15.07

MX$29.71

49.3%

Accent Group (ASX:AX1)

A$2.11

A$4.19

49.6%

Saigon Thuong Tin Commercial Bank (HOSE:STB)

₫38750.00

₫76325.14

49.2%

Com2uS (KOSDAQ:A078340)

₩48250.00

₩96043.58

49.8%

Shenzhen Anche Technologies (SZSE:300572)

CN¥18.75

CN¥36.88

49.2%

Click here to see the full list of 906 stocks from our Undervalued Stocks Based On Cash Flows screener.

Let's explore several standout options from the results in the screener.

BlueNord

Overview: BlueNord ASA is an oil and gas company engaged in the exploration, development, and production of hydrocarbon resources across Norway, Denmark, the Netherlands, and the United Kingdom with a market cap of NOK18.26 billion.

Operations: The company's revenue is primarily derived from its oil and gas exploration and production segment, totaling $702.30 million.

Estimated Discount To Fair Value: 32.9%

BlueNord ASA is currently trading at a significant discount, approximately 32.9% below its estimated fair value of NOK1026.61, indicating potential undervaluation based on discounted cash flows. Despite recent challenges leading to a net loss of US$70.8 million in 2024, the company forecasts robust annual revenue growth of 12.8%, outpacing the Norwegian market average and signaling future profitability within three years, although interest payments are not well covered by earnings presently.

OB:BNOR Discounted Cash Flow as at Feb 2025
OB:BNOR Discounted Cash Flow as at Feb 2025

Bonesupport Holding

Overview: Bonesupport Holding AB (publ) is an orthobiologics company that develops and commercializes injectable bio-ceramic bone graft substitutes across Europe, North America, and internationally, with a market cap of SEK22.70 billion.